Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Abzena Completes ADC Tech Transfer | Contract Pharma

What are you searching for?

Sign in
Breaking News

Abzena Completes ADC Tech Transfer

Successful technical transfer of Synaffix GlycoConnect ADC Technology to enable use in client projects

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Abzena has completed a technology transfer and scalability evaluation using the Synaffix technologies of GlycoConnect (antibody conjugation) and HydraSpace (highly polar spacer). Familiarity with these antibody-drug conjugate (ADC) technologies adds to Abzena’s expertise in process development and GMP manufacturing of ADC linkers and payloads. Abzena can now rapidly ramp up ADC projects using Synaffix technology with high scientific quality.
 
“Abzena believes in patient first drug development,” said Jonathan Goldman, chief executive officer, Abzena. “Our expertise and experience with Synaffix GlycoConnect and HydraSpace technology further advances our leadership across multiple platforms in ADC. We look forward to supporting our customers as they leverage Synaffix technology to rapidly advance ADCs from IND stage into early clinical development.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics